In this study, we compare three methods for determining hormone receptor status in relation to recurrence-free interval (RFi) and overall survival (OS) in premenopausal breast cancer patients treated with tamoxifen compared to a control group in a randomised trial with long-term follow-up. Here, NR4A1 is linked to breast cancer.